Abstract
Early clinical development of anticancer drugs is beset with obstacles unique to this type of therapy. Typical healthy volunteer studies are seldom possible, and patients tend to have end-stage malignant processes, with many underlying symptoms and often organ dysfunction. This chapter will focus on the design of traditional early phase I clinical trials of anticancer therapies, including selection of patients, starting dose selection, dose-escalation approaches, and endpoints. It will go on to examine the limitations of the current, widely accepted approaches and some of the problems facing investigators. Finally, it will also discuss how early anticancer drug development now faces a paradigm shift due to the advent of novel, molecularly targeted anticancer drugs.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Arbuck SG (1996) Workshop on phase I study design. Ninth NCI/EORTC New Drug Development Symposium, Amsterdam, March 12, 1996. Ann Oncol 7:567–573
Baselga J, Averbuch SD (2000) ZD1839 (‘Iressa’) as an anticancer agent. Drugs 60(Suppl 1):33–40
Booth CM, Calvert AH, Giaccone G, Lobbezoo MW, Seymour LK, Eisenhauer EA (2008) Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT). Eur J Cancer 44:19–24
Burtles SS, Newell DR, Henrar RE, Connors TA (1995) Revisions of general guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe. The Cancer Research Campaign (CRC) Phase I/II Clinical Trials Committee and the European Organization for Research and Treatment of Cancer (EORTC) New Drug Development Office. Eur J Cancer 31A:408–410
Denis LJ, Verweij J (1997) Matrix metalloproteinase inhibitors: present achievements and future prospects. Invest New Drugs 15:175–185
Evans WE, Rodman JH, Relling MV, Crom WR, Rivera GK, Pratt CB, Crist WM (1991) Concept of maximum tolerated systemic exposure and its application to phase I-II studies of anticancer drugs. Med Pediatr Oncol 19:153–159
Fox E, Curt GA, Balis FM (2002) Clinical trial design for target-based therapy. Oncologist 7:401–409
Kerbel RS (2001) Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results. J Clin Oncol 19:45S–51S
Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC (2001) Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol 19:265–272
Newell DR (1990) Phase I clinical studies with cytotoxic drugs: pharmacokinetic and pharmacodynamic considerations. Br J Cancer 61:189–191
Newell DR, Burtles SS, Fox BW, Jodrell DI, Connors TA (1999) Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics. Br J Cancer 81:760–768
O’Quigley J, Pepe M, Fisher L (1990) Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics 46:33–48
O’Quigley J, Shen LZ (1996) Continual reassessment method: a likelihood approach. Biometrics 52:673–684
Penta JS, Rosner GL, Trump DL (1992) Choice of starting dose and escalation for phase I studies of antitumor agents. Cancer Chemother Pharmacol 31:247–250
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Glen, H., Cassidy, J. (2014). Phase I Trials in Oncology: Design and Endpoints. In: Rudek, M., Chau, C., Figg, W., McLeod, H. (eds) Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. Cancer Drug Discovery and Development. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-9135-4_6
Download citation
DOI: https://doi.org/10.1007/978-1-4614-9135-4_6
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-9134-7
Online ISBN: 978-1-4614-9135-4
eBook Packages: MedicineMedicine (R0)